Samsung has decided to retire one of its newer health metrics from Galaxy Watches sold in the United States. The move comes barely a year after the company introduced the feature with much fanfare. Vascular Load, which promised insights into cardiovascular stress during sleep, will vanish for American users with the arrival of One UI 9 Watch in late July. The change arrives alongside Samsung Health version 7.0.
Users first learned of the decision through an in-app notice. It appeared quietly in the Samsung Health app. The notice informed them that Vascular Load would no longer be available after the update. They can still download their existing data before it disappears. But the feature itself stops working in the US. Elsewhere in the world it continues unchanged.
The company isn’t leaving customers without options. Samsung plans to introduce Blood Pressure Trend as the direct replacement. This new tool tracks blood pressure patterns over time. It delivers periodic measurements and offers lifestyle suggestions based on the results. Yet it comes with a key requirement. Owners must calibrate the watch using an external blood pressure cuff. Accuracy improves when they repeat the cuff measurement at least once every 28 days.
Vascular Load operated differently. It relied on the watch’s optical heart rate sensor to capture photoplethysmogram waveforms overnight. The system analyzed changes in blood volume and vessel stiffness. From those signals it estimated overall stress on the vascular system. No extra hardware was needed. Wear the watch to bed for at least three nights out of the previous 14. Insights then appeared automatically in the Samsung Health app. The metric reflected influences from diet, exercise, stress and rest.
Industry observers point to regulatory pressure as the likely driver. Samsung has not stated an official reason. Many online discussions highlight the strict oversight from the Food and Drug Administration. Features that skirt too close to medical claims often face hurdles in the US market. Similar speculation surfaced on forums and social platforms immediately after the announcement. One common refrain captured the frustration. “We can’t have nice features because of the FDA.”
This isn’t the first time Samsung has adjusted its health offerings to satisfy regulators. The company already offers blood pressure monitoring on Galaxy Watches in select countries. That capability requires initial calibration with a cuff too. In the United States the blood pressure feature has operated under wellness disclaimers rather than full medical clearance. The same language applies to the incoming Blood Pressure Trend. Samsung stresses it supports general wellness only. The tool is not intended for diagnosis or treatment of any medical condition.
Analysts see the shift as pragmatic. Vascular Load launched as an experimental feature in the Labs section of the app. It carried explicit disclaimers about its limitations. The metric provided directional guidance rather than clinical precision. Still, its removal leaves some early adopters disappointed. They had grown accustomed to the overnight cardiovascular feedback. Now that data stream ends for US owners.
The replacement focuses on a more established vital sign. Blood pressure trends can reveal patterns tied to daily habits. Samsung says the feature will suggest adjustments to improve overall heart health. Yet the cuff dependency adds friction. Not every user keeps a validated arm cuff at home. Those who do must remember to recalibrate regularly. The process echoes the setup already required for existing Samsung blood pressure tools.
Recent coverage highlights the speed of the change. TechRadar reported the discontinuation and the alternative on the same day the news broke. The publication noted user theories about FDA compliance. It also detailed how the new trend feature aims to deliver ongoing insights after the initial setup.
Android Authority confirmed the late-July timing tied to One UI Watch 9. The site explained that previous Vascular Load readings will disappear unless exported. It added that the Blood Pressure Trend builds on Samsung’s earlier blood pressure capabilities rolled out this year.
SamMobile obtained the exact notice text from the Samsung Health app. The publication reported that the feature had remained in beta since its debut on the Galaxy Watch 7 and Watch Ultra. It speculated the FDA link without confirmation from Samsung. The story also mentioned the simultaneous launch window for the Galaxy Watch 9 series later this month.
9to5Google provided further technical context. The outlet described how Vascular Load used PPG data to assess blood flow and vessel stress. It emphasized that the metric aimed to help users reduce cardiovascular risk through better habits. The replacement, according to the report, maintains the wellness-only framing.
Broader questions remain about Samsung’s health strategy. The company continues to expand its BioActive sensor capabilities. Body composition measurements via bioelectrical impedance analysis have drawn both praise and scrutiny. Independent studies have tested the accuracy of those readings against clinical gold standards. Some research finds strong correlation for certain metrics. Others urge caution when interpreting results for medical decisions.
Meanwhile, Samsung partners with institutions to validate its tools. A recent collaboration with Massachusetts General Hospital examines how Galaxy Watch data can support patients on GLP-1 medications. The study tracks body composition changes and activity levels during weight-loss treatment. Such efforts suggest the company wants its wearables taken seriously in clinical settings even as individual features face regulatory limits in consumer markets.
For US Galaxy Watch owners the practical impact is immediate. Those who relied on Vascular Load must adapt. They can export historical data through the app settings under personal data options. After the update they will see the new Blood Pressure Trend module instead. The transition happens automatically with the software push. No action is required beyond the usual update process.
Observers expect the Galaxy Watch 9 and Watch Ultra 2 to highlight the Blood Pressure Trend during their upcoming launch. The devices will likely emphasize long-term trend analysis over single-point measurements. Samsung has not detailed whether the new feature will incorporate elements of the old Vascular Load algorithm. For now the two appear as distinct experiences.
The episode reveals tensions in consumer health technology. Companies race to deliver novel metrics that feel personal and actionable. Regulators demand evidence and clear boundaries between wellness and medicine. The result is a patchwork of availability. A feature thrives in one country but disappears in another. Users adapt or switch ecosystems.
Samsung’s decision keeps its US product compliant. It also redirects focus toward blood pressure, a metric with wider acceptance and established clinical value. Whether the trade-off satisfies owners depends on how useful they find the cuff-based workflow. Early reactions on social media show mixed feelings. Some welcome more concrete blood pressure data. Others lament the loss of a completely passive overnight metric.
One thing is clear. The wearables market keeps evolving. Features arrive, mature, and sometimes get retired. Samsung’s latest move trims one experimental offering while expanding another. US customers will soon test the replacement in real life. The rest of the world keeps both tools for the time being. And the company moves forward with its next hardware cycle already on the horizon.
WebProNews is an iEntry Publication